VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC.

CourtDistrict Court, D. New Jersey
DecidedJanuary 11, 2021
Docket3:18-cv-13635
StatusUnknown

This text of VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC., (D.N.J. 2021).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

IN RE JUBLIA Case No. 3:18-cv-13635 (BRM) (LHG)

OPINION

MARTINOTTI, DISTRICT JUDGE Before this Court are the applications by Plaintiffs Bausch Health US, LLC, Bausch Health Ireland Limited, Bausch Health Americas, Inc., and Kaken Pharmaceutical Co., Ltd. (“Karen”) (collectively, “Plaintiffs”) and Defendants Aleor Dermaceuticals Ltd. (“Aleor”), Aurobindo Pharma Limited and Aurobindo Pharma USA Inc. (collectively, “Aurobindo”), KVK-Tech, Inc. (“KVK”), Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, “Lupin”), and Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, and Cadila Healthcare Limited (collectively, “Zydus”) (together with Aleor, Aurobindo, KVP, and Lupin, “Defendants”) for claim construction to resolve disputes over two claim terms: “bottom portion” and “tip portion.” (ECF Nos. 190–91 & 204–05.) This Court has examined the disputes over the construction of these claim terms and, for the reasons set forth in this Opinion, and for good cause shown, this Court defines the disputed claim term “bottom portion” to mean “the lateral surface that is bonded to the tubular body,” and “tip portion” to mean “the fan-shaped end of the columnar brush member.” I. BACKGROUND A. Factual Background This case arises out of an action for infringement of Karen’s patent, U.S. Patent No. 10,478,601 (“the ’601 patent”), by Defendants’ filing of an Abbreviated New Drug Application (“ANDA”) seeking U.S. Food and Drug Administration (“FDA”) approval to market a generic version of Plaintiffs’ product Jublia®—an efinaconazole topical solution, 10%. (ECF No. 191 at 5.) On November 19, 2019, the United States Patent and Trademark Office (“PTO”) issued

the ’601 patent, which describes a solution applicator “with which irritation on an affected part of a patient may be reduced even when a solution is used.” (ECF No. 191-2 at 3.) Onychomycosis is an infection of the nail unit caused by fungi. (ECF No. 191 at 6–7.) The parties dispute the proper construction of two claim terms “bottom portion” and “tip portion” used in the ’601 patent. The chart below sets forth the parties’ proposed constructions. Claim Language Asserted Claims Plaintiffs’ Proposed Defendants’ Construction Proposed Construction “bottom portion” ’601 patent claim 8 Plain and ordinary “the lateral surface meaning, i.e., “the that is bonded to the lateral surface that is lowest end of the bonded to the tubular tubular body of the body” bottomed tubular holder” “tip portion” ’601 patent claim 8 Plain and ordinary “fan-shaped end of the meaning, i.e., “end columnar brush portion of the member” columnar brush member”

B. Procedural History On September 6, 2018, Plaintiffs filed a Complaint asserting claims of infringement against Defendants. (ECF No. 1.) On March 5, 2019, Defendants filed an Answer to the Complaint along with counterclaims asserting the noninfringement and invalidity of the patents-in-suit. (ECF No. 20.) On September 18, 2020, both Plaintiffs and Defendants filed their opening Markman briefs. (ECF Nos. 190 & 191.) On October 7, 2020, both Plaintiffs and Defendants filed their Markman reply briefs. (ECF Nos. 204 & 205.)1 II. LEGAL STANDARD

Claims define the scope of the inventor’s right to exclude. Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005). Claim construction determines the correct claim scope and is a determination reserved exclusively for the court as a matter of law. Markman v. Westview Instruments, Inc., 52 F.3d 967, 978–79 (Fed. Cir. 1995) (en banc). Indeed, the court can only interpret claims and “can neither broaden nor narrow claims to give the patentee something different than what [it] has set forth” in the specification. E.I. Du Pont de Nemours & Co. v. Phillips Petroleum Co., 849 F.2d 1430, 1433 (Fed. Cir. 1998). A court’s determination “of patent infringement requires a two-step process: first, the court determines the meaning of the disputed claim terms, then the accused device is compared to the claims as construed to determine infringement.” Acumed LLC v. Stryker Corp., 483 F.3d 800, 804 (Fed. Cir. 2007).

This interpretive analysis begins with the language of the claims, which is to be read and understood as it would be by a person of ordinary skill in the art. Dow Chem. Co. v. Sumitomo Chem. Co., 257 F.3d 1364, 1372 (Fed. Cir. 2001); see also Markman v. Westview Instruments, Inc., 52 F.3d 967, 986 (Fed. Cir. 1995) (en banc), aff’d, 517 U.S. 370 (1996) (holding that “[t]he focus [in construing disputed terms in claim language] is on the objective test of what one of ordinary skill in the art at the time of invention would have understood the term to mean”); Phillips, 415 F.3d at 1312–13. In construing the claims, the court may examine both intrinsic evidence (e.g.,

1 Plaintiffs and Defendants agreed a claim construction hearing is not necessary because the issues can be decided on the papers without argument. (ECF No. 206.) the patent, its claims, the specification, and the prosecution history) and extrinsic evidence (e.g., expert reports and testimony). Pitney Bowes, Inc. v. Hewlett-Packard Co., 182 F.3d 1298, 1309 (Fed. Cir. 1999). The analysis of claim language begins with determining the “ordinary and customary

meaning of a claim term[, which] is the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Phillips, 415 F.3d at 1313. Further, the language should not be read solely in the context of the claim under review; instead, it should be analyzed “in the context of the entire patent” and with an understanding of how that language is used in the field from which the patent comes. Id. In conducting this review, a different interpretation is placed on a term located in an independent claim than on those located in dependent claims, and it is understood that each claim covers different subject matters. Saunders Grp., Inc. v. Comfortrac, Inc., 492 F.3d 1326, 1331 (Fed. Cir. 2007) (quoting Phillips, 415 F.3d at 1315 (holding that “the presence of a dependent claim that adds a particular limitation gives rise to a presumption that the limitation in question is

not present in the independent claim”)). In reviewing the language of a patent, “the court starts the decision-making process by reviewing the same resources as would [a person or ordinary skill in the art in question], viz., the patent specifications and the prosecution history.” Phillips, 415 F.3d at 1313 (quoting Multiform Desiccants, Inc. v. Medzam, Ltd., 133 F.3d 1473, 1477 (Fed. Cir. 1998)). When “the ordinary meaning of claim language as understood by a person of skill in the art [is] readily apparent,” understanding claim construction “involves little more than the application of the widely accepted meaning of commonly understood words.” Phillips, 415 F.3d at 1314. “In such circumstances, general purpose dictionaries may be helpful” to explain the terms used. Id. Often times, however, the ordinary meaning of the claim language is not readily apparent, and in such circumstances, courts look to “those sources available to the public that show what a person of skill in the art would have understood disputed claim language to mean.” Id. (quoting Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc., 381 F.3d 1111, 1116 (Fed. Cir. 2004).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

iLight Technologies, Inc. v. Fallon Luminous Products Corp.
380 F. App'x 978 (Federal Circuit, 2010)
Ecolab, Inc. v. FMC Corp.
569 F.3d 1335 (Federal Circuit, 2009)
Computer Docking Station Corp. v. Dell, Inc.
519 F.3d 1366 (Federal Circuit, 2008)
Oatey Co. v. IPS CORP.
514 F.3d 1271 (Federal Circuit, 2008)
Innogenetics, N v. v. Abbott Laboratories
512 F.3d 1363 (Federal Circuit, 2008)
In Re Translogic Technology, Inc.
504 F.3d 1249 (Federal Circuit, 2007)
Ormco Corp. v. Align Technology, Inc.
498 F.3d 1307 (Federal Circuit, 2007)
Saunders Group, Inc. v. Comfortrac, Inc.
492 F.3d 1326 (Federal Circuit, 2007)
Acumed LLC v. Stryker Corporation
483 F.3d 800 (Federal Circuit, 2007)
Honeywell International, Inc. v. ITT Industries, Inc.
452 F.3d 1312 (Federal Circuit, 2006)
Collegenet, Inc. v. Applyyourself, Inc.
418 F.3d 1225 (Federal Circuit, 2005)
Seachange International, Inc. v. C-Cor, Inc.
413 F.3d 1361 (Federal Circuit, 2005)
August Technology Corp. v. Camtek, Ltd.
655 F.3d 1278 (Federal Circuit, 2011)
In Re Gilbert P. Hyatt
708 F.2d 712 (Federal Circuit, 1983)
Thorner v. Sony Computer Entertainment America LLC
669 F.3d 1362 (Federal Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/valeant-pharmaceuticals-north-america-llc-v-zydus-pharmaceuticals-usa-njd-2021.